区分人表皮生长因子受体2(HER2)低表达与HER2过表达乳腺癌:四种MRI扩散模型的比较研究
前瞻性纳入158例乳腺癌患者,比较传统DWI、连续时间随机游走(CTRW)、分数阶微积分(FROC)和拉伸指数模型(SEM)鉴别HER2状态的价值。HER2低表达组αCTRW、DCTRW、βFROC、DFROC、μFROC、αSEM和DDCSEM低于HER2过表达组;αCTRW是单一最佳鉴别指标(AUC=0.802),高于ADC(AUC=0.610),联合ER状态、PR状态和肿瘤大小后AUC提升至0.877。
要点
- HER2低表达乳腺癌的αCTRW、DCTRW、βFROC、DFROC、μFROC、αSEM和DDCSEM值低于HER2过表达乳腺癌。
- αCTRW是鉴别HER2低表达与HER2过表达乳腺癌的单一最佳扩散指标(AUC=0.802)。
- αCTRW联合ER状态、PR状态和肿瘤大小可将AUC提升至0.877。
核心结论
- αCTRW有助于鉴别HER2低表达与HER2过表达乳腺癌。
研究设计与样本
- 前瞻性研究纳入158例女性,均行DWI、CTRW、FROC和SEM检查,病理分为HER2零表达组(n=10)、HER2低表达组(n=86)和HER2过表达组(n=62)。
关键影像表现/征象
- HER2低表达组αCTRW、DCTRW、βFROC、DFROC、μFROC、αSEM和DDCSEM值显著低于HER2过表达组(p<0.001至p=0.01)。
- HER2低表达组与HER2过表达组的ER状态、PR状态和肿瘤大小存在差异(p<0.001至p=0.009)。
诊断标准与关键数值
- αCTRW鉴别HER2低表达与HER2过表达乳腺癌的AUC为0.802,高于ADC的0.610(p<0.05)。
- αCTRW联合ER状态、PR状态和肿瘤大小后AUC为0.877。
临床应用与阅片要点
- αCTRW可作为鉴别HER2低表达与HER2过表达乳腺癌的扩散MRI指标。
- 联合ER状态、PR状态和肿瘤大小可提高αCTRW的鉴别能力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the value of conventional DWI, continuous-time random walk (CTRW), fractional order calculus (FROC), and stretched exponential model (SEM) in discriminating human epidermal growth factor receptor 2 (HER2) status of breast cancer (BC).
METHODS: This prospective study included 158 women who underwent DWI, CTRW, FROC, and SEM and were pathologically categorized into the HER2-zero-expressing group (n = 10), HER2-low-expressing group (n = 86), and HER2-overexpressing group (n = 62). Nine diffusion parameters, namely ADC, αCTRW, βCTRW, DCTRW, βFROC, DFROC, μFROC, αSEM, and DDCSEM of the primary tumor, were derived from four diffusion models. These diffusion metrics and clinicopathologic features were compared between groups. Logistic regression was used to determine the optimal diffusion metrics and clinicopathologic variables for classifying the HER2-expressing statuses. Receiver operating characteristic (ROC) curves were used to evaluate their discriminative ability.
RESULTS: The estrogen receptor (ER) status, progesterone receptor (PR) status, and tumor size differed between HER2-low-expressing and HER2-overexpressing groups (p < 0.001 to p = 0.009). The αCTRW, DCTRW, βFROC, DFROC, μFROC, αSEM, and DDCSEM were significantly lower in HER2-low-expressing BCs than those in HER2-overexpressing BCs (p < 0.001 to p = 0.01). Further multivariable logistic regression analysis showed that the αCTRW was the single best discriminative metric, with an area under the curve (AUC) being higher than that of ADC (0.802 vs. 0.610, p < 0.05); the addition of ER status, PR status, and tumor size to the αCTRW improved the AUC to 0.877.
CONCLUSIONS: The αCTRW could help discriminate the HER2-low-expressing and HER2-overexpressing BCs.
CLINICAL RELEVANCE STATEMENT: Human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC) might also benefit from the HER2-targeted therapy. Prediction of HER2-low-expressing BC or HER2-overexpressing BC is crucial for appropriate management. Advanced continuous-time random walk diffusion MRI offers a solution to this clinical issue.
KEY POINTS: • Human epidermal receptor 2 (HER2)-low-expressing BC had lower αCTRW, DCTRW, βFROC, DFROC, μFROC, αSEM, and DDCSEM values compared with HER2-overexpressing breast cancer. • The αCTRW was the single best diffusion metric (AUC = 0.802) for discrimination between the HER2-low-expressing and HER2-overexpressing breast cancers. • The addition of αCTRW to the clinicopathologic features (estrogen receptor status, progesterone receptor status, and tumor size) further improved the discriminative ability.
引用
- Mao C, Hu L, Jiang W, et al. Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models. Eur Radiol. 2023. PMID: 37672055. doi:10.1007/s00330-023-10198-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。